Clinical Trials Logo

Intestinal Diseases clinical trials

View clinical trials related to Intestinal Diseases.

Filter by:

NCT ID: NCT02073526 Completed - Ulcerative Colitis Clinical Trials

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

Start date: May 2013
Phase: N/A
Study type: Observational [Patient Registry]

Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.

NCT ID: NCT02065089 Completed - Ulcerative Colitis Clinical Trials

Development of 'Emma'--a Pediatric IBD Quiz

Start date: February 6, 2014
Phase: N/A
Study type: Interventional

We would like to collaborate and further develop an ipad-based, interactive quiz game 'Emma'; to identify gaps in knowledge of inflammatory bowel disease in pediatric patients. These gaps can be used to improve patient education.

NCT ID: NCT02048137 Completed - Clinical trials for Inflammatory Bowel Disease

Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases

tDCS in IBD
Start date: January 2014
Phase: Phase 2
Study type: Interventional

In the study we test whether transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases. Hypothesis: Transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases.

NCT ID: NCT02020382 Completed - Healthy Clinical Trials

Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases

MicroMICI
Start date: December 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the diagnostic value of microRNAs in IBD colon (ulcerative colitis or Crohn's disease) in adults as compared to healthy controls (and non-IBD colitis)

NCT ID: NCT02010268 Completed - Clinical trials for Enteropathy, Necrotizing Enterocolitis

Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates

CALPROPREMA
Start date: September 30, 2013
Phase: N/A
Study type: Interventional

This study aims to evaluate a clinico-biological predictive score, associating the faecal calprotectin, for the diagnosis of enterocolitis and enteropathy of the preterm neonates.

NCT ID: NCT01990716 Completed - Crohn Disease Clinical Trials

Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases

MICILIP
Start date: February 2013
Phase: N/A
Study type: Interventional

We will quantify one of the lipid compounds (5,6 epoxy eicosatrienoic acid (5,6 EET), 5,6- EpoxyEicosaTrienoic acid) in colonic biopsies of Inflammatory Bowel Disease patients. We will evaluate its possible use as a pathological activity biomarker and its potential as a therapeutic target. We hypothesized that 5,6-EET is present in human colonic tissues in varying quantities depending on the pathological state of the IBD patient.

NCT ID: NCT01984879 Completed - Clinical trials for Inflammatory Bowel Disease

Vaccination Status, Knowledge and Attitude in Korean Patients With IBD

Start date: November 2013
Phase:
Study type: Observational

The purpose of this study is to investigate the vaccination status, knowledge about vaccination, and attitude to vaccination of the Korean patients with inflammatory bowel diseases

NCT ID: NCT01981889 Completed - Clinical trials for Inflammatory Bowel Disease 11

Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease

Start date: October 2013
Phase: Phase 4
Study type: Interventional

Steroid is commonly used to treat autoimmune disorders such as rheumatoid arthritis, lupus, and inflammatory bowel disease (Crohn's Disease and Ulcerative Colitis). However, its use is associated with numerous systemic side-effects, including diabetes, osteoporosis, and potentially significant mood changes. The investigators wish to determine how common patients with inflammatory bowel disease experience mood changes when they take steroid for their disease.

NCT ID: NCT01974869 Completed - Clinical trials for Inflammatory Bowel Diseases

Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response

Start date: March 2014
Phase: N/A
Study type: Observational [Patient Registry]

Background: The immunologic response to stress is regulated by the cytokines. Anti-Tumor Necrosis Factor-α agents are antibodies directed against a key cytokine in the process angiogenesis and collagen synthesis. It is not known whether they intervene with surgical stress response increasing the rate of postoperative complications. Method: Un-blinded prospective, non-interventional cohort single centre study including all the patients with Crohn's disease and Ulcerative Colitis undergoing abdominal surgery. Immunological and endocrinological parameters will measured in blood samples taken from these patients before and after surgery. Power calculations showed that 17 patients in each arm are needed.

NCT ID: NCT01971970 Completed - Clinical trials for Inflammatory Bowel Diseases

Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

Start date: October 2013
Phase:
Study type: Observational

Anti-TNF treatment (infliximab (IFX), adalimumab (ADA)) has become standard therapy for refractory pediatric and adult Crohn's disease (CD) patients, and is used for the induction (primary response) and maintenance of remission. When effective, clinical and endoscopic remission is reached within weeks. However, primary non-response is observed in 20% of pediatric patients, and in 40% of adult CD patients, suggesting a more robust acute response to anti-TNF therapy in children as compared to adults.During maintenance treatment, 60 - 80% of patients have secondary loss of response, necessitating dose adjustments to maintain clinical response. Anti-TNF treatment is also increasingly used in ulcerative colitis (UC), and has been shown to induce remission in active disease. For UC, the comparison between the efficacy in children versus adults is more difficult to report as studies in children are scarce. Anti-TNF treatment is associated with rare but potentially fatal side effects, infusion reactions, and is an expensive treatment. To avoid overtreatment it is necessary to early identify non-responders to treatment, and therefore it is important to develop predictive biomarkers of treatment response.